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Implementation science is the study of 
methods to promote the systematic 
uptake of evidence based interventions 
into practice and policy to improve 
health. Despite the need for high 
quality evidence from implementation 
research, randomised trials of 
implementation strategies often have 
serious limitations. These limitations 
include high risks of bias, limited use of 
theory, a lack of standard terminology 
to describe implementation strategies, 
narrowly focused implementation 
outcomes, and poor reporting. This 
paper aims to improve the evidence 
base in implementation science by 
providing guidance on the 
development, conduct, and reporting 
of randomised trials of implementation 
strategies. Established randomised trial 
methods from seminal texts and recent 
developments in implementation 
science were consolidated by an 
international group of researchers, 
health policy makers, and practitioners. 
This article provides guidance on the 
key components of randomised trials 
of implementation strategies, including 
articulation of trial aims, trial 
recruitment and retention strategies, 
randomised design selection, use of 
implementation science theory and 
frameworks, measures, sample size 
calculations, ethical review, and trial 
reporting. It also focuses on topics 
requiring special consideration or 
adaptation for implementation trials. 
We propose this guide as a resource for 
researchers, healthcare and public 
health policy makers or practitioners, 
research funders, and journal editors 
with the goal of advancing rigorous 
conduct and reporting of randomised 
trials of implementation strategies.
Investments in health research are not fully realised 
because of delayed and variable uptake of effective 
interventions by health systems and professionals.1-3 
Implementation science seeks to resolve this problem 
by generating evidence to facilitate the use and 
integration of evidence based interventions into 
health policy and practice.4 Just as well conducted 
randomised clinical trials can provide robust estimates 
of the effects of medical and surgical treatments, 
well conducted randomised trials of implementation 
strategies (which we refer to as implementation 
trials) can provide robust assessments of the effects 
of implementation strategies. These strategies include 
audit and feedback, training, or reminders, on 
measures of the uptake and integration of evidence 
based interventions in healthcare and public health 
practice.5
Although randomised trials are central to evidence 
based medicine6 and are a common evaluation design 
in the field of implementation science,7 concerns have 
been raised about the quality of implementation trials. 
Criticisms include high risks of bias, limited use of 
theory, a lack of standardised terminology to describe 
implementation strategies, limited measures, and poor 
reporting.7-11 Progress in the field, however, has been 
rapid with recent advances in implementation science 
theory, concepts, terminology, measures, and reporting 
standards to resolve many of these limitations.12-14
This article draws on recent developments in 
implementation science with established randomised 
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Summary pointS
Criticisms of current implementation trials include risks of bias, lack of theory 
use, lack of standardised terminology to describe implementation strategies, 
and limited measures and poor reporting
This article consolidates recent methodological developments in implementation 
science with established guidance from seminal texts of randomised trial 
methods to provide best practice guidance to improve the development and 
conduct of randomised implementation trials
Consideration of such guidance will improve the quality and use of randomised 
implementation trials for healthcare and public health improvement
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trial methods to provide a best practice guide to 
improve the development, conduct, and reporting of 
randomised implementation trials. This guidance was 
authored by an international interdisciplinary group 
with expertise spanning implementation science, 
health services research, behavioural science, public 
health, trial methods, biostatistics, and health policy 
and practice. It discusses application of randomised 
trial methods in the context of large scale trials of 
implementation strategies, focusing on aspects that 
might be unique to implementation studies. Table 
1 defines key implementation terms used in the 
guide.
recommendations for the development, conduct, and 
reporting of randomised implementation trials
When is an implementation trial warranted?
Implementation trials generate scientific knowledge 
to improve the uptake of evidence based interventions 
in practice. Researchers should consider several factors 
when deciding whether a trial of implementation 
strategies is needed,19 primarily the following:
•	 A healthcare or public health intervention that is 
supported by evidence as effective (ideally by a 
systematic review of trials);
•	 A known evidence-practice gap—that is, verifi-
cation that the evidence based intervention is not 
routinely implemented in practice;19 20 and
•	 Equipoise regarding the effects of an implemen-
tation strategy.
The need for a trial and the trial methods used 
should also be guided by the needs, values, and 
input of end users and other stakeholder groups. 
A range of guidance documents are available to 
identify appropriate groups to engage and undertake 
meaningful research co-design across all phases of trial 
design, conduct, and dissemination.21-23 Key features 
of successful co-design include clearly articulated 
roles and responsibilities in the process, research 
training to end users, clear communication pathways, 
and frequent interactions between researchers and 
end users.24
Statement of the implementation trial aim
Randomised implementation trials should have 
precisely stated aims, defining the population, 
intervention, comparison, and outcome under 
investigation. They should also distinguish clearly 
between the aims of the implementation strategy 
and the therapeutic intent of the targeted evidence 
based intervention.12 For example: “The study 
aimed to assess the effectiveness of audit and 
feedback (implementation strategy), relative to 
usual practice (implementation comparison) for 
improving clinician (implementation population) 
provision (implementation outcome, and target of 
the implementation strategy) of nicotine replacement 
therapy (clinical intervention) to inpatients of a cardiac 
ward to support smoking cessation (therapeutic intent 
of the clinical intervention).”
Randomised implementation trials can assess the 
effect of a given strategy on implementation outcomes 
alone, or assess both the effectiveness of the intervention 
on clinical or population health therapeutic outcomes 
as well as the effect of the implementation strategy on 
implementation outcomes.25 Trials with a dual focus 
are known as effectiveness-implementation hybrid 
trials (table 2). Type I effectiveness-implementation 
hybrid designs aim to evaluate the effects of an 
evidence based intervention and describe or better 
understand the context for implementation, but do 
not test an implementation strategy.25 Type II and 
III hybrid trials test implementation strategies on 
implementation outcomes.25 Although hybrid designs 
are suggested to be an efficient means of accumulating 
evidence to inform implementation, the contribution 
of type I and II trials to this end could be limited. This 
limitation could be the case when research design 
considerations to preserve the robust assessment 
of clinical effectiveness questions are prioritised 
over those considerations to assess the effect of 
an implementation strategy (on implementation 
outcomes).
As an example, a type II hybrid trial could express 
dual aims as follows: “The primary aims of the 
study were to: i) assess the effectiveness of audit 
and feedback (implementation strategy), relative 
to usual practice (implementation comparison) for 
improving clinician (implementation population) 
provision (implementation outcome, and target of 
the implementation strategy) of nicotine replacement 
therapy (clinical intervention); and ii) to assess 
the effectiveness of nicotine replacement therapy 
(clinical intervention), relative to usual care, in impro-
ving smoking cessation (therapeutic outcome and 
therapeutic intent of the clinical intervention) among 
cardiac inpatients (therapeutic population).”
Table 1 | Definitions of key terms in implementation science
Term Definition
Implementation science Scientific study of methods to promote the systematic uptake of evidence based interventions into practice and policy to improve health4
Implementation strategy Method or technique used to enhance the adoption, implementation, and sustainability of an evidence based intervention15
De-implementation Process of identifying and removing non-evidence based interventions that are harmful, not cost effective, or ineffective16
Evidence based intervention Evidence based practice, model of care, programme, policy, process, or guideline recommendation that is being implemented17
Implementation outcomes Process-of-care or quality measures (or related measures for public health) to assess the effects of the implementation strategy15 17
Implementation trial Research design testing the effects of implementation strategies on implementation outcomes5
Clinical (therapeutic) trial Research that investigates the effect of a treatment or other intervention on patient health outcomes18
Adaptation Degree to which an evidence based intervention is changed (eg, during intervention delivery) to suit the needs of the  setting or the target population17
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Recruitment and retention
Implementation trials usually recruit and randomise 
staff or organisations rather than individual patients. 
Intervention effects on clinical practice are often 
assessed using routinely collected, anonymised data. 
Therefore, implementation trials can be conducted at 
relatively low cost, with potentially more complete trial 
data than those from clinical trials that require intensive 
recruitment and follow-up of patients.26 27 Nonetheless, 
effective recruitment and retention approaches are 
needed to ensure that all participant groups (patients, 
clinicians, health services) are broadly representative 
of the populations for which the findings are intended 
to generalise. Minimising barriers to participation 
is therefore critical to maximise external validity. 
Consent procedures for participants to opt out could 
be appropriate in some circumstances and can result 
in high levels of participation,28 recruitment of more 
typical participants groups, and more generalisable 
effects.29-31 Opt out consent was recently used, for 
example, in a randomised trial of mail-outs and phone 
calls to improve adherence to secondary preventive 
treatment after myocardial infarction that used 
administrative data for outcome assessment.32
For research using active consent procedures, 
recruitment and retention strategies recommended for 
patients in clinical trials (such as dedicated recruitment 
coordinators) and reminders for non-responders 
also apply to the recruitment of patient groups in 
implementation trials. Researchers can also leverage 
the networks of relevant professional associations or 
governing health authorities,33 34 engage potential trial 
sites in the design of the study and its recruitment and 
retention strategies to minimise the potential burden 
of participation, ensure acceptability, and facilitate 
the recruitment of health organisations and clinicians. 
Because implementation trials aim to promote evi-
dence based practice, they could be more attractive 
to clinicians and organisations than other types of 
research, particularly when stepped wedge or delayed 
control group designs are used as all sites receive 
implementation support as part of, or immediately 
following, follow-up data collection.
Underlying trial philosophy: pragmatic and 
explanatory trials
Explanatory trials use methods that prioritise internal 
validity, and are undertaken in more ideal research 
conditions.35 Pragmatic trials emphasise external 
validity using methods more closely aligned to real 
world contexts.35 Explanatory trials focus on questions 
asking whether the intervention (or implementation 
strategy) “can” work. Implementation trials are 
inherently pragmatic because they usually focus on 
Table 2 | Typical characteristics of conventional clinical or public health trials, effectiveness-implementation hybrid trials, and implementation trials. 
Adapted from Curran et al, 2012, with permission25
Conventional clinical 
(therapeutic) or  
public health trial
Effectiveness-implementation hybrid trials (type)
Implementation trialI II III
Research aim
To assess the  
therapeutic effects of a 
clinical or public health 
intervention on  
individual patient or 
population health 
outcomes
Primary: to assess the 
therapeutic effectiveness of 
a clinical or public health 
intervention on individual 
patient or population health 
outcomes; secondary: to 
describe or better understand 
the context for implementation
Co-primary: to assess the therapeutic 
effectiveness of a clinical or public health 
intervention on individual patient or  
population health outcomes; and to assess 
the effects of a strategy to implement a 
clinical or public health intervention on 
implementation outcomes
Primary: to assess the effects of a  
strategy to implement a clinical or 
public health intervention on  
implementation outcomes; secondary: 
to describe individual or population 
therapeutic health outcomes associated 
with implementation of an intervention
To assess the effects of a 
strategy to implement a 
clinical or public health  
intervention on  
implementation outcomes
Target of experimental manipulation (intervention or implementation strategy)
Individual patients, 
community members,  
or populations
Individual patients, community 
members, or populations
Both individual patient’s community 
members, or populations; and clinicians, 
policy makers, service providers or medical 
or public health systems responsible for 
implementation
Primary: clinicians, policy makers, 
service providers or medical or public 
health systems responsible for  
implementation; secondary:  
individual patients, community  
members or populations
Clinicians, policy makers, 
service providers or medical 
or public health systems  
responsible for  
implementation
Effects of therapeutic intervention on patient or population health outcomes of interest
Explicitly tested Explicitly tested Explicitly tested Not tested; known to be effective Not tested; known to be 
effective
Effects of implementation strategy on implementation outcomes
Typically not  
considered or required 
as intervention delivery 
is usually at the control 
of, or administered by 
researchers
Not tested Explicitly tested Explicitly tested Explicitly tested
Trial outcome measures
Clinical conditions,  
patient symptoms, 
health behaviours, 
disease risk factors, or 
other patient or  
population health  
related outcomes
Clinical conditions, patient 
symptoms, health behaviours, 
disease risk factors, or other 
patient or population health 
related outcomes
Both: clinical conditions, patient symptoms, 
health behaviours, disease risk factors, 
or other patient or population health 
related outcomes; professional practice 
improvement, changes in processes of care, 
adherence to clinical standards, quality of 
intervention delivery or other  
implementation outcomes
Primary: professional practice  
improvement, changes in processes of 
care, adherence to clinical standards, 
quality of intervention delivery or other 
implementation outcomes; secondary: 
health service use, clinical conditions, 
patient symptoms, health behaviours, or 
other health related outcomes
Professional practice  
improvement, changes in  
processes of care, adherence 
to clinical standards, quality 
of intervention delivery or  
other implementation 
outcomes
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whether an intervention (or implementation strategy) 
“does” work when delivered in routine clinical or 
public health contexts.35 As such, the effect sizes of 
interventions tested in pragmatic trials are typically 
smaller than those reported in explanatory trials.36 37
The pragmatic explanatory continuum indicator 
summary tool (PRECIS-2) describes the methodo-
logical characteristics of explanatory and pragmatic 
trials and can help researchers undertaking imple-
mentation trials to make design decisions consistent 
with the intended purpose and pragmatic nature 
of implementation trials.38 The tool requires users 
to consider trial eligibility criteria, recruitment 
methods, setting, the expertise and resources required 
for intervention implementation, the degree of 
flexibility in the implementation and adherence to 
the intervention, follow-up procedures, the selection 
of relevant primary outcome measures, and analysis. 
Furthermore, pragmatic trials might require departures 
from conventional safety and integrity monitoring 
processes, which have been largely designed for 
explanatory studies. Simon et al offer some guidance 
of adaptations that could be appropriate across 
each of the key participant safety and trial integrity 
obligations.39
Research trial design considerations
Non-randomised study designs are often used in 
implementation research on the basis that they might 
be more appropriate or feasible than a randomised 
controlled trial. However, these designs could report 
misleading estimates of effect even when experimental 
groups appear similar on important prognostic factors, 
and when such factors are considered in analyses.40 
Randomised trials have also been suggested to be 
unnecessary in instances when extreme effects are 
anticipated, for example, when relative risks are less 
than 0.25 or greater than 4.41 However such effect 
sizes are rarely reported in implementation trials. 
Because the process of random assignment of an 
adequate number of units can effectively eliminate 
the risk of confounding, randomised trials provide the 
most robust evidence of the effects of implementation 
strategies. Further, with improving access and 
opportunity to use existing routinely collected data 
such as registries and electronic medical records, such 
designs are increasingly feasible.41 42
Nonetheless, randomised trials require inter-
ventions that can feasibly be assigned at random. 
Examination of the impact of national level legisla- 
tive or regulatory changes on professional practice, 
for example, are unlikely to be amenable to evalua-
tion using randomised designs. Complex, adaptive 
systems based strategies, and those developed 
using complexity theory, have been tested as part 
of randomised implementation trials,43 44 but there 
are many challenges to doing so, particularly for 
interventions in open systems without clearly defined 
boundaries.45 Randomised trials of such strategies 
may include mixed method research approaches, 
in-depth case studies, and ethnographic narratives 
to better understand system interconnectedness, 
interactions, and impact.45 The development of 
evaluation methods of these types of interventions 
has been identified as a priority, and are beginning 
to emerge.46 47
A variety of randomised trial designs can be used 
in implementation trials (table 3). Researchers 
undertaking implementation trials should be aware of 
the relative merits of different randomised designs to 
inform appropriate design selection.55 56 A thorough 
description of randomised trial design limitations 
(and strengths) is provided elsewhere and summarised 
in supplementary file 1.55 57 Here, we discuss the 
level of randomisation considerations, and describe 
randomised trial designs that can be applied to assess 
the effects of implementation strategies.
Level of randomisation
In an individually randomised trial, individual 
participants (that is, patients)55 are randomised to 
one of two or more parallel groups, and outcomes (eg, 
clinical effectiveness) are measured at the same level 
as the unit of randomisation (patient). Such trials 
are relatively uncommon in implementation research 
given that interventions often operate at multiple 
levels and involve changes to health systems. Most 
implementation trials using random assignment, 
therefore, use cluster randomised designs (also called 
group randomised designs).7 In these designs, clusters 
such as hospitals or clinicians are randomised to receive 
support to implement an evidence based interven-
tion (an implementation strategy) or a comparison 
condition, but where implementation outcome data 
can be collected from multiple individuals (that is, 
patients) within each cluster.55 Such outcome data 
are usually correlated, and this clustering must be 
accounted for in the design and analysis to obtain valid 
statistical inferences.58
Many levels of clustering are possible in imple-
mentation trials: for example, patients can be 
clustered within clinicians, who could themselves be 
clustered within a hospital, and hospitals could be 
clustered within a healthcare organisation. The unit 
of randomisation should be carefully chosen to reflect 
the trial aims, and should consider trade-offs between 
randomising at a higher level to prevent contamination 
versus randomising at a lower level to increase 
the number of units available for randomisation. 
Contamination likely occurs even in cluster randomised 
trial designs where individual clinicians within a 
hospital are allocated to implementation training 
and support, and then pass on such implementation 
resources or knowledge to clinicians in the same 
hospital allocated to a control condition. In such cases, 
randomising at the level of the hospital or organisation 
rather than the clinician can help mitigate this risk. On 
the other hand, if the contamination is not substantial, 
randomising at a lower level might be preferable, from 
a statistical efficiency perspective.59 The higher the 
level of randomisation, the fewer groups (eg, clinics, 
hospital) may be available to be randomised.
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Parallel, two arm, randomised trial
Parallel, two arm, randomised implementation trials 
compare the effects of an implementation strategy 
with those of a control or alternative implementation 
strategy. Conduct of two arm trials is useful when the 
effects of one implementation strategy are primarily 
of interest. These trials are more feasible than multi-
arm trials and are the most common randomised 
design used to assess the effects of implementation 
strategies.60 61
Multi-arm randomised trials
Multi-arm randomised trials provide information about 
the comparative effects of multiple implementation 
approaches. They represent a more efficient method 
of testing the effects of implementation strategies 
than performing sequential two arm trials.49 For 
example, including three arms in a randomised 
implementation trial could enable the comparison of 
two implementation strategies with each other as well 
as a comparison condition. In randomised factorial 
designs, participants (or clusters) are randomised into 
groups comprised of combinations of the experimental 
conditions. Researchers interested in testing the 
effects of implementation strategy A as well as those 
of implementation strategy B within the same trial, 
for example, might randomise participants into four 
groups: A alone, B alone, both A and B, and neither A 
nor B.55 Such designs enable exploration of interactions 
between groups, and the effects of implementation 
strategies separately and in combination. Fractional 
factorial randomised trials include larger numbers 
of strategies, however, and allocate participants to 
selected (rather than all) strategy combinations, 
eliminating comparisons that are of no interest to 
reduce the potential sample size requirements of the 
trial.62 63
When an intervention must, for practical, logistical, 
or organisational reasons, be rolled out to all units 
in a health system, a stepped wedge design might be 
useful. In stepped wedge randomised trials,57 64 all 
units such as hospitals (clusters) are first recruited, 
then randomised to receive the implementation 
intervention at regular intervals (or steps) sequentially 
over time, until all units have been exposed to the 
intervention.65  66 Trial outcome data are collected at 
regular intervals throughout the trial, with each unit 
providing data for both experimental and control 
conditions (periods). Under some circumstances, the 
design might require fewer units to participate than 
parallel arm, cluster randomised trials, particularly 
when the intraclass correlation is high and cluster 
period sizes are large. Stepped wedge trials require 
repeated assessment of outcomes across the trial 
periods, making these designs most suited for outcomes 
that can be assessed using routinely collected data. 
Table 3 | Description and key considerations of randomised designs for assessing the effects of implementation interventions
Description Considerations Example
Two arm, parallel randomised trial48
Individuals or groups (eg, clinics or schools) 
consisting of multiple individuals  
(eg, patients) are randomly assigned to 
receive a treatment (implementation strategy) 
or an alternative condition (eg, usual practice 
or control)
Most appropriate when sample size or trial  
resources are limited, and when there is an  
interest in assessing the effect of one  
implementation strategy compared with current 
practice or an alternative implementation strategy
To evaluate the effectiveness of an implementation intervention to improve 
six guideline recommended, health professional behaviours in managing 
type 2 diabetes in primary care, 44 general practices were randomised to 
implementation support or usual care control. Implementation support was 
provided to clinicians within general practices allocated to receive it, while 
the primary outcome included a patient survey of a random sample of  
patients per practice that reported receipt of updated diabetes education 
advice as well as routinely collected prescribing data for blood pressure, 
insulin initiation for glycaemic control, and foot examinations from practice 
records across practices26
Multi-arm randomised trial49
Investigate the effects of two or more  
implementation strategies versus a  
comparison (or alternative strategy) at the 
same time. Such designs can involve  
individual or cluster randomisation
Most appropriate when sample sizes are large, 
when there is an interest in assessing the relative 
effects of different implementation strategies 
alone or in combination, and where there is 
good control over the implementation strategies 
provided to each group
To promote the uptake of evidence based guidance on blood transfusion in 
surgery, a 2×2 factorial, cross sectional, cluster-randomised controlled trial 
allocated NHS trusts* to receive one of the following: standard feedback 
reports (usual care), standard reports with follow-on support, enhanced 
reports, or enhanced reports with follow-on support. The primary outcome for 
each topic will be the proportion of patients receiving a transfusion coded as 
unnecessary using data from a national audit50
Stepped wedge randomised trials51
Following a baseline period, an  
implementation strategy is sequentially 
provided to clusters. The order in which the 
different clusters are assigned to receive the 
implementation strategy is randomised. Over 
time, all units will have received  
implementation support
Most appropriate when a decision has been 
made to roll out an implementation strategy 
across a health system, when risks of bias are 
low, and when routinely collected data are  
available for outcome assessment
To improve the delivery of evidence based cardiovascular care in primary 
care, practices were randomly assigned by region to receive implementation 
support 12, 24, or 36 months after initiation of baseline data collection. The 
primary outcome was mean adherence to indicators of evidence based care 
as measured by chart review of a randomly selected cohort of 66 patients 
per practice (measured before, during, and after receipt of implementation 
support)52
Sequential trial design: sequential multiple assignment randomised trial53
Intervention dose, type, or delivery of an 
implementation strategy (or intervention) is 
modified at several stages based on specified 
decision rules. At each stage, the participant 
is randomly (re)assigned to one of several  
implementation strategy (intervention) 
options
Can be used to help many practical decisions 
regarding how best to support improvements in 
implementation. Most appropriate for the  
development of adaptive implementation  
strategies when a sufficient sample is available, 
and where there is good control over the  
implementation strategies provided to each 
group
To evaluate the effectiveness of a sequential approach to sustainment of a 
postpartum depression prevention programme (EIAU) in outpatient clinics, 
clinics at risk of not sustaining programme implementation will be randomised 
to receive either no additional implementation support (that is, EIAU only), 
or low intensity coaching and feedback (LICF). If clinics receiving LICF are still 
at risk at subsequent assessments, they will be randomised to either LICF or 
high intensity coaching and feedback. The primary outcome includes percent 
sustainment of implementation of core programme elements54
*Trusts in the United Kingdom’s health service.
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Such designs are increasingly being used in health 
services and implementation research, although they 
are vulnerable to increased risks of bias and other 
complexities that could make them less attractive than 
parallel arm designs.64 65 67
Sequential trial designs
Sequential multiple assignment randomised trials 
(SMART) are a type of adaptive design used to inform 
the development of adaptive implementation strategies 
(or interventions).53 68 In an adaptive implementation 
strategy, the dose, type, or delivery of strategies is 
modified across several stages based on prespecified 
decision rules, providing individualised approaches 
to better meet the specific needs and evolving status 
of participants. With this design, participants are 
randomised to different implementation strategy 
options at each stage.68 For example, clinicians who 
do not improve implementation of an intervention 
following the provision of an initial package of 
implementation strategies could receive different or 
more intensive implementation support subsequently 
than clinicians who do improve implementation. 
The design allows researchers to assess the effect of 
adaptive approaches and the isolation of the effects of 
specific strategy modifications. Such designs involve 
complex statistical considerations.
Hybrid trials
Hybrid trials can use any type of randomised trial 
design. However, because they focus on assessing the 
effects of implementation strategies on both clinical 
effectiveness and implementation outcomes, design 
modification might be needed (table 3).25 Design 
modifications may often be required because clinical 
effectiveness outcomes are usually assessed at an 
individual level, while implementation outcomes 
could be assessed at a provider or organisational level. 
This duality of purpose of hybrid trialscan result in 
research designs to assess outcomes at one level being 
nested within a design determined by an outcome at 
another level. For example, a randomised trial of the 
introduction of a school nutrition policy might require 
100 schools to participate to detect meaningful change 
in school level policy implementation (implementation 
outcome), but need only to assess students in a nested 
random sample of 20 participating schools to identify 
meaningful improvements in child dietary intake 
(effectiveness outcome).
Reducing bias in randomised implementation trials
Researchers should be aware that randomised trials are 
prone to threats to internal validity and seek to avoid 
major risks of bias.56 As implementation trials often 
include multiple outcomes assessed at different levels 
(organisation, clinician, patient), research design 
characteristics and risk of bias need consideration at 
each level. For cluster trials, baseline comparability of 
groups at both the cluster and individual levels can be 
difficult to achieve if only a small number of clusters 
such as hospitals are available for randomisation.69 70
In many cluster implementation trials, study sites 
(clusters) such as clinics, might be randomised and 
allocated before individual (that is, patient level) 
recruitment. If those identifying and recruiting 
participants (or the potential participants themselves) 
are not blinded to allocation, differential recruitment 
and study participation can occur (selection bias).71 
Selection bias is a common problem in clustered 
designs.72 In the UK BEAM trial, for example, primary 
care practices were recruited and randomised.73 
Clinicians at primary care practices allocated to the 
experimental arm then received training in guideline 
based management of back pain after which patient 
recruitment commenced. In the study, practice nurses 
recruited twice as many patients among primary care 
practices allocated to receive training as those patients 
allocated to usual care, and the characteristics of 
patients differed between groups. Gatekeepers can also 
withdraw their health site (cluster) from a trial once 
informed of group allocation but before individual 
participant level recruitment.71 Such circumstances 
can be particularly challenging for intention-to-treat 
approaches to analyses of trial outcomes, because little 
is known about the characteristics of those individuals 
who would have participated in that cluster.74 
Selection bias can best be avoided by allocating units 
after consent and baseline data collection.
In clinical trials, a lack of blinding of participants 
and personnel delivering an intervention in a clinical 
trial could increase the risk of bias,55 because 
knowledge of assignment to an intervention might 
lead to contamination, protocol deviations, or co-
intervention. However, the blinding of participants and 
personnel is often inappropriate (and not possible) in 
implementation trials because they seek to assess the 
effect of an implementation strategy in individuals 
or organisations aware of the care given. A range of 
other strategies could reduce the risks of such biases 
including the use of clustered designs,75 simply asking 
clinicians or patients not to share information, trial 
intervention or implementation strategy sessions that 
are spatially or temporally separate, and systems to 
avoid transfer of patients between clinicians.76 The 
effectiveness of these strategies, however, is unclear. If 
adequately assessed, statistical approaches can also be 
used to adjust for contamination in analyses.77-79 The 
Cochrane risk-of-bias tool (version 2)56 for randomised 
trials provides a comprehensive description of 
potential risks of bias for various randomised designs 
and strategies to help identify and reduce such risks.
Models, theories, and frameworks
The lack of explicit descriptions of the mechanism by 
which implementation strategies are hypothesised 
to exert their effects is suggested to reduce the ability 
to judge the generalisability of trial findings across 
settings and contexts, to limit understanding of 
implementation processes and to slow the cumulative 
progression of the field.80-83 As such, implementation 
trials should include an explicit programme theory,81 or 
a logic model that details the rationale and assumptions 
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about the mechanisms linking implementation 
strategy (and intervention),84 processes, and inputs to 
trial outcomes. A programme theory can be developed 
using informal theory—that is, understanding of 
the problem and its determinants gained through 
experience or tacit knowledge by the developers of the 
intervention. However, we recommend that the use of 
informal theory is coupled with the formal behavioural 
or implementation theories or frameworks (table 4).85 
Although a range of theories and frameworks exist, few 
are supported empirically,93 and some are known to be 
of little use in predicting or explaining behaviour.94 
Determinant frameworks can be particularly useful 
in implementation strategy development because 
they consolidate several behavioural theories and 
identify a comprehensive range of multilevel factors 
that are theoretically (or empirically) linked with 
implementation outcomes. In addition to the extent to 
which a theory or framework is empirically supported, 
criteria including usability, testability, familiarity, and 
applicability should be considered when comparing 
and selecting a model, theory, or framework.95
Several useful resources are available to support 
the application of formal theory in the development of 
broader programme models and specific implementation 
strategies.96 French et al propose a four step process 
for such a development (table 5).97 Other systematic 
methods for developing implementation strategies also 
exist,99 100 which typically involve four common steps: 
barrier identification, linking barriers to implementation 
strategy component selection, use of theory, and 
user engagement.99 Importantly, the development of 
programme theory and implementation strategies 
requires a thorough understanding of the problem, its 
determinants, and context in which implementation 
needs to occur and so should involve considerable end 
user engagement and formative evaluation.100
Measures
Trial outcome measures
The selection of outcome measures should be linked 
directly to trial primary and secondary aims and enable 
the robust quantification of an effect. Proctor and 
colleagues proposed a taxonomy of eight conceptually 
distinct implementation outcomes, namely accepta-
bility, adoption, appropriateness, feasibility, fidelity, 
implementation cost, penetration, and sustaina-
bility.101 From a trial design perspective, the collective 
labelling of such measures as “outcomes,” is a 
misnomer that has created some confusion,102 because 
many of these measures do not lend themselves to the 
reporting of an effect size. For example, measures of 
the acceptability of an intervention (or implementation 
strategy) can only be reported in the trial group in 
receiving it, precluding between group comparisons. 
Many of these measures might be better aligned to the 
assessment of implementation processes and other 
factors influencing implementation.42 102
Most implementation trials primarily focus on 
measuring the extent to which an implementation 
strategy achieved implementation of the targeted 
evidence based intervention (eg, a guideline) such 
as measures of professional practice improvement, 
changes in processes of care, adherence to clinical 
standards, or the amount or quality of programme or 
intervention delivery.7 As measures of such outcomes 
are often unique to the intervention being implemented 
and its context, generic standard measures are 
unlikely to be available. Instead, researchers might 
identify or develop measures that assesses their 
specific implementation outcome and context, for 
example, using data collected as part of environmental 
observations, routinely collected administrative 
records, or questionnaires. The limitations of each 
of these approaches need to be considered,103 but as 
Table 5 | Suggested steps for the development of a theory informed implementation strategy. Adapted from French et al, 201297
Steps Description
1 Identify who (eg, individuals or professional groups) needs to do what differently in order for implementation to be improved98
2 Using informal and formal theory and frameworks, identify barriers and enablers that need to be resolved, and articulate a pathway of change for the targeted  
behaviour change to occur. A variety of research methods, including literature reviews and local qualitative and quantitative data collection, should be used to  
support the development of the change pathway (programme theory)
3 Select implementation strategies (behaviour change techniques, modes of delivery) that might be effective, locally relevant, acceptable, and feasible to overcome 
identified barriers and enhance facilitators to change. Selection of strategies could be based on matrices recommended by determinant frameworks, empirical  
evidence, and engagement with end users
4 Decide how change in implementation can be robustly and feasibly measured, including factors on the hypothesised casual pathway (mediators) and appropriate 
implementation outcomes
Table 4 | Description of models, theories, and frameworks used in implementation strategy design. Adapted from Nilsen, 201585
Theory or framework type Description Application
Classic theories (eg, theory of planned  
behaviour, social cognitive theory, situated  
change theory)86-88
Originate from related disciplines (eg, psychology) and help  
understand or explain individual, group, or organisational  
behaviour. They describe precise mechanisms of behaviour change
Classic and implementation theories describe precise 
mechanisms of behaviour and behaviour change. One or 
more of these theories can be used to developed targeted 
implementation strategies and describe how change in the 
behaviour of those involved in an implementation process 
is anticipated to occur
Implementation theories (eg, implementation 
climate, organisational readiness to change, 
normalisation process theory)89-91
Theories developed (or adapted classical theories) specifically to 
understand, explain, and inform implementation. They describe 
precise mechanisms of change for one or more aspect of  
implementation
Determinants frameworks (eg, consolidated  
framework for implementation research,  
theoretical domains framework)14 92
Often developed through the consolidation of constructs from of 
a range of theories, they aim to understand and explain factors that 
could influence (facilitate or impede) implementation. They typically 
do not describe mechanisms for change
Determinants frameworks can help identify factors thought 
to be associated with implementation, and implementation 
strategies that can be used to address these, from which 
programme theory can be developed
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trial outcomes, such measures should be robust, and 
sensitive to change. Multiple outcome measures should 
also be used in trials to provide a more comprehensive 
appraisal of the effects of an implementation strategy, 
acknowledging how these measures are related to 
each other and the inherent limitations of single 
measures of implementation.42 103 For trials focused 
on assessment of individual patient level outcomes, 
clinical outcomes should be sufficiently proximal and 
arise exclusively (or mostly) from the improvements 
in clinical practice targeted by the implementation 
strategy.104 For example, in a study to improve survival 
from heart attack, researchers noted that even if perfect 
compliance with care standards in a hospital could be 
achieved, the anticipated changes in cardiac mortality 
(or survival) would be insufficient to feasibly detect in 
a trial.105
Process evaluation
Process evaluation provides important depth to the 
interpretation of trial outcomes. Qualitative and 
mixed method approaches can elucidate insights 
to better understand how and why implementation 
might improve (or not) following the application 
of an implementation strategy, and key contextual 
factors that might influence it. Several publications, 
including a white paper by the Qualitative Research 
in Implementation Science (QualRIS) group (an expert 
group convened by the National Institute of Health), 
provide guidance for the use of qualitative methods 
in implementation science, including discussion of 
design, data collection, and analytical methods as well 
as recent developments in the field.106 107 While several 
approaches have been suggested to undertake process 
evaluations,108-111 here we offer guidance consistent 
with the United Kingdom’s Medical Research Council, 
which suggests process evaluations include assessment 
of implementation processes, mechanism of impact, 
and contextual factors that shape outcomes.112
Implementation processes
Implementation processes are specific policies, 
practices, and strategies that are used to establish 
and support an intervention.101Table 6 provides 
a range of measures proposed by Proctor et al101 
that might be useful for exploring implementation 
processes. Such measures, for example, could be 
used to describe characteristics of the evidence based 
intervention, or the implementation strategy (table 6). 
The psychometric properties of a range of existing tools 
that assess these have recently been reported.113 114 
Additionally, because evidence based interventions are 
often adapted by end users (such as clinicians) in the 
process of their implementation, the documentation, 
recording, and reporting of adaptations has been 
suggested to be important to understanding the effects 
of efforts to implement evidence based interventions.12 
A framework by Stirman et al provides more detailed 
guidance of how to do so.115 The use of qualitative 
inquiry has also been recommended by QualRIS to 
assess adaptation and other implementation processes 
while ethnography has been suggested to be well 
suited to assess implementation microprocesses at the 
level of individual interactions.107
Implementation mechanisms
The mechanism by which an implementation 
strategy exerts its effects is important to understand 
in order to identify how these effects might be 
replicated and improved.112 To develop such an 
understanding, specific analytical methods can be 
applied to assess casual assumptions of the pathways 
specified by the programme theory.116-119 Such 
mechanistic evaluations require clear specification 
of implementation strategies, links between strategy 
and mechanism, identification of outcomes, and (if 
relevant) articulation of effect modifiers.119 Some 
classic theories, implementation theories, and deter- 
minants frameworks have existing measures of 
factors theoretically linked to implementation out-
comes. Several reviews of such measures have been 
published,120 of which the most comprehensive is the 
Instrument Review Project, funded by the National 
Institutes of Health.13 Reviews, however, suggest that 
implementation mechanisms are rarely tested in trials 
of implementation strategies,121 122 and where testing 
has occurred, often it is undertaken inappropriately. To 
best understand the multilevel and interdependence 
of factors that might influence implementation, 
sophisticated quantitative and qualitative methods 
are required.123 124 Lewis and colleagues suggest 
that common quantitative approaches to mediation 
Table 6 | Implementation measures used to establish and support evidence based interventions. Adapted from Proctor et al, 2011, with permission101
Measures Description
Acceptability Perception among implementation stakeholders that an evidence based intervention (or implementation strategy) is agreeable, palatable, or satisfactory
Adoption Intention, initial decision, or action to try or use an evidence based intervention (or implementation strategy). Adoption also can be referred to as “uptake”
Appropriateness Perceived fit, relevance, or compatibility of an evidence based intervention (or implementation strategy) for a given practice setting, provider, or consumer; or perceived fit of the innovation to resolve a particular issue or problem
Feasibility Extent to which an evidence based intervention (or implementation strategy) can be successfully used or carried out
Fidelity Degree to which an evidence based intervention (or implementation strategy) was delivered as it was intended
Cost  
(incremental or implementation cost) Cost or relative cost of the implementation of an evidence based intervention
Penetration Integration of an evidence based intervention within a service setting and its subsystems
Sustainability Extent to which a newly implemented evidence based intervention is maintained or institutionalised within a  service setting’s ongoing, stable operations
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testing in implementation trials are suboptimal, and 
that the product of coefficients approach might be 
preferable given its capacity to examine single level 
and multilevel mediation and maximise power.122 
Further, qualitative approaches have been suggested 
to be particularly useful in the absence of established 
quantitative measures, and structured qualitative 
inquiry can help deepen an understanding of 
mechanistic processes.107  122 Contemporary guidance 
on mechanistic evaluation, including how it is applied 
in implementation science, is provided in more detail 
elsewhere.122
Implementation contexts
Context refers to external factors that might act as a 
barrier or facilitator to implementation, or influence 
the effects of an implementation strategy.12 112 
Descriptions of context, therefore, provide critical 
information regarding the external validity of trial 
findings and enable readers to assess the applicability 
of the findings to their own setting. Context measures 
can include measures of the social, political, or 
economic environment that might influence imple-
mentation.12 These measures include leadership, 
workforce capacity, readiness to change, and other 
organisational or patient characteristics.125 Some 
randomised implementation trials have also used 
systematic reviews of news archives, and of websites 
of relevant agencies to assess changes in government 
policy, guidelines, accreditation standards or funded 
programmes that might influence implementation 
or confound trial outcomes.126 127 Quantitative or 
qualitative measures of context can also be assessed 
analytically to examine their potential role in shaping 
implementation processes or outcomes in the context 
of the broader programme theory.42
Sample size calculation
Sample size calculations estimate the number of 
participants required to detect the hypothesised 
effect of an implementation strategy with acceptable 
power.128 129 While sample size calculations for 
clinical effectiveness trials are based on treatment 
effects identified as of sufficient magnitude to provide 
a clinical therapeutic benefit to a patient,129 sample 
size calculations for implementation trials need to 
consider a meaningful or worthwhile effect size for an 
implementation outcome from a population or system 
level perspective. Because implementation strate-
gies typically seek to improve the implementation 
of existing evidence based interventions of known 
therapeutic benefit, any improvement in imple-
mentation may increase the number of patients or 
the community exposed to (and benefiting from) 
evidence based healthcare. Strategies that lead to 
small improvements in implementation might be 
meaningful from a system perspective if they can 
be delivered, easily, at low cost, and at a population 
level. Sample size calculations need to use parameters 
required for the type of randomised design undertaken 
and researchers should follow design specific advice 
to do so.130 Because implementation trials can have 
participants at multiple levels, sample size calculations 
are usually more complicated than those for clinical 
effectiveness trials, and might need to consider the 
relative contributions to the power of increasing the 
numbers of participants at each level.
Research ethics review
As implementation trials meet the definition of 
research (a systematic investigation designed to 
produce generalisable knowledge) and involve human 
research participants (which could include health 
professionals),131 ethical review by an institutional 
review board is required before trial commencement. 
Implementation trials can occur in the context of usual 
service improvement activities that can complicate 
the nature of consent for research participation.132 133 
Implementation trials often involve participants at 
multiple levels, so research ethics review is more 
complicated. Although no specific ethical statements 
exist pertaining to implementation trials,133 the 
Ottawa Statement on the Ethical Design and Conduct of 
Cluster Randomised Trials covers such issues, and has 
recently been applied to trials of knowledge translation 
interventions.134 135 The statement provides guidance 
to help identify research participants (patients, 
clinicians, and managers), and lists requirements for 
organisational governance, assessing benefits and 
harms, and protecting vulnerable participants (table 
7). A key consideration when submitting a protocol 
to a research ethics committee is identifying the 
human research participants in the trial.136 Research 
participants can be identified as any individual 
whose interests might be affected as a result of study 
interventions or data collection procedures.136 In 
some implementation trials, patients might not be 
considered research participants (that is, they do not 
have any study interventions directed at them, or 
do not have their identifiable data collected for the 
purposes of research). When patients are not research 
participants, their informed consent is not required.137 
However, when employees such as clinicians are the 
recipients of an implementation strategy, and are 
involved in data collection or where identifiable data 
are collected about them, their consent is required. 
Approval might also be required from gatekeepers 
such as an organisational leader for such research to 
be undertaken in their facility.
Reporting
The Standards for Reporting Implementation Studies 
(StARI) guide has been designed specifically to 
facilitate the better reporting of implementation trials 
and should be used in conjunction with the CONSORT 
reporting guideline (and extension) specific to the 
type of randomised trial design used.12 Efforts to test 
the effectiveness of implementation strategies have 
been hindered by a lack of conceptual clarity owing 
to inconsistent definitions and insufficient detail to 
enable replication.9 To resolve this, StaRI recommend 
the use of the Template for Intervention Description 
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and Replication (TIDieR) checklist when describing 
the evidence base intervention that is subject to 
implementation.12 138 Similar recommendations have 
been proposed for standardising description of 
implementation strategies,15 and implementation 
researchers should describe implementation strategies 
using an established taxonomy (eg, the Behaviour 
Change Technique or Expert Recommendations for 
Implementation Change taxonomies).9 15 139 140 The 
identification of core and non-core components of 
the implementation strategy, based on the underlying 
programme theory, should also be articulated.
Conclusion
High quality randomised trials have a key role in 
advancing implementation science by providing robust 
evidence on the effects of approaches to improve the 
uptake and integration of evidence based practice. With 
the emergence of more accepted concepts, terminology, 
processes, and reporting standards in the field, the 
opportunity to improve the development, conduct, and 
reporting of such trials is considerable.12-14 This article 
summarises the latest guidance on the best practice 
randomised trial and implementation science methods 
to fulfil this need for improvement. The development 
of guidance documents have proved a useful resource 
in improving the rigour of randomised controlled trials 
in healthcare and public health.141 This guide is also 
aimed at journal editors, reviewers, and funders of 
implementation research as a resource to improve the 
quality of the implementation science evidence base.
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